跳至主要内容
临床试验/NCT01073111
NCT01073111撤回不适用

Assessment of Neointimal Stent Strut Coverage and Endothelial Function After Second Generation Drug-Eluting Stent Systems

Hyogo Medical University1 个研究点 分布在 1 个国家开始时间: 2010年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
试验地点
1
主要终点
To compare coronary endothelial function after primary angioplasty.

研究概览

简要总结

The purpose of this study is to compare coronary endothelium function in patients with a zotarolimus-eluting versus a sirolimus-eluting or a everolimus-eluting stents with optical coherence tomography, vasoconstriction in response to acetylcholine, and coronary biomarker level.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Significant coronary de novo lesion (> 70% by quantitative angiographic analysis)
  • •Patients with stable or acute coronary syndrome considered for coronary revascularization
  • •Reference vessel diameter of 2.5 to 3.5 mm by operator assessment

排除标准

  • •Contraindication to anti-platelet agents
  • •Ostial lesion within 5 mm from ostium
  • •Different DES in other vessel simultaneously
  • •Creatinine level 2.5 mg/dL
  • •Left main stenosis more than 50%.
  • •vein graft lesion
  • •Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries
  • •Life expectancy 1 year
  • •Reference vessel < 2.5 mm or > 4.0 mm diameter by visual
  • •Long lesion that require more than three stents

研究组 & 干预措施

zotarolimus-eluting stents (ENDEAVOR®)

Active Comparator

干预措施: zotarolimus-eluting stent (ENDEAVOR®) (Device)

sirolimus-eluting stents (CYPHER SELECT® PLUS)

Active Comparator

干预措施: sirolimus-eluting stents (CYPHER SELECT® PLUS) (Device)

everolimus-eluting stents (PROMUS®)

Active Comparator

干预措施: everolimus-eluting stents (PROMUS®) (Device)

结局指标

主要结局

To compare coronary endothelial function after primary angioplasty.

时间窗: 6 months and 12 months

To compare the presence of neointimal stent strut coverage via optical coherence tomography.

时间窗: 6 months and 12 months

To compare the serum biomarker levels measured in coronary artery blood.

时间窗: 6 months and 12 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kenichi Fujii

Assistant Professor

Hyogo Medical University

研究点 (1)

Loading locations...

相似试验